论文部分内容阅读
Purpose: Intratumor hypoxia is a hallmark of hepatocellular carcinoma cells(HCC),leading to therapeutic resistance and malignant progression.Various strategies have been developed to combat with the hypoxia.The present study found a novel anti-FAK/ALK inhibitor CT-707 approved by China FDA for Phase I clinical trial,exhibited superior antitumor effects under hypoxia,and uncover the function and mechanism of CT-707,thus providing a promising therapeutic strategy for HCC therapy.